Showing 6671-6680 of 9762 results for "".
- Exosome News: ExoCoBio Completes Acquisition of Benevhttps://practicaldermatology.com/news/exosome-news-exocobio-completes-acquisition-of-benev/2461855/ExoCoBio has acquired a majority ownership in BENEV, a global medical aesthetic company that produces growth factor-based skincare products. ExoCoBio produces exosome-based regenerative aesthetics and medicine products and currently holds 54 patents and 15 scientific publicati
- WCD News: Connect Biopharma's Rademikibart Earns High Marks in ADhttps://practicaldermatology.com/news/wcd-news-connect-biopharmas-rademikibart-earns-high-marks-in-ad/2461851/Four new studies support the efficacy and safety of rademikibart in atopic dermatitis (AD), Connect Biopharma reports. Rademikibart (CBP-201), a next-generation IL-4Rα antibody, achieved all primary and secondary endpoints in a randomized pivotal trial for moderate-to-severe
- MRA's RARE Registry for Acral & Mucosal Melanoma Surpasses 100-Patient Milestonehttps://practicaldermatology.com/news/mras-rare-registry-for-acral-mucosal-melanoma-surpasses-100-patient-milestone/2461850/The Melanoma Research Alliance’s (MRA) RARE Registry for acral and mucosal melanoma has officially surpassed 100 patie
- AD Pipeline Watch: Eblasakimab Monthly Dosing Shows Promise in Phase 2b AD Studyhttps://practicaldermatology.com/news/eblasakimab-monthly-dosing-shows-promise-in-phase-2b-ad-study/2461845/ASLAN Pharmaceuticals’ eblasakimab met the primary endpoint of percent change from baseline in the Eczema Area and Severity Index (EASI) score at week 16 versus placebo in adult patients with moderate-to-severe atopic dermatitis (AD), according to results from the Phase 2b dose-ra
- WCD News: Experts Excited About Ornovi’s Next Generation JAK Inhibitorhttps://practicaldermatology.com/news/wcd-news-experts-excited-about-ornovis-next-generation-jak-inhibitor/2461833/Ornovi's OR-101 is a highly selective next generation JAK3-ITK inhibitor with potentially a better safety profile than JAK inhibitors currently on the market, according to a presentation at the 25th World Congress of Dermatology Meeting 2023 in Singapore. Seemal Desa
- Biosimilar Update: Humira Biosimilar Cyltezo Now Available in U.S.https://practicaldermatology.com/news/biosimilar-update-humira-biosimilar-cyltezo-now-available-in-us/2461831/Boehringer Ingelheim’s Cyltezo (adalimumab-adbm), a U.S. Food and Drug Administration (FDA)-approved Interchangeable biosimilar to Humira (adalimumab), is now commercially available in the U.S. Cyltezo was initially approved as a biosimilar in 2017 for use in multi
- New Microneedle Patch May Treat Acne Without Antibioticshttps://practicaldermatology.com/news/new-microneedle-patch-may-treat-infected-acne-without-antibiotics/2461826/Researchers out of the University of Hong Kong (HKUMed) have designed a new microneedle patch that offers a non-antibiotic approach for the treatment of infected acne. The design is engineered with ultrasound-responsive zinc-based metal-organic framework (MOF) antibacterial nanoparticle
- Oro Health, Dermago Unveil Consumer Version of its AI-powered Dermatology Assessment and Recommendation Toolhttps://practicaldermatology.com/news/oro-health-dermago-unveil-consumer-version-of-its-ai-powered-dermatology-assessment-and-recommendation-tool/2461822/Oro Health and Dermago are unveiling the public version of DermSmart, a tool designed to classify skin types and minor skin conditions. This new AI-driven version offers patients the ability to upload pictures of their skin condition, ask questions and interact with the tool i
- News Your Patients Can Use: AAD Offers Sun Protection Counsel in Advance of Independence Day Holiday Weekendhttps://practicaldermatology.com/news/news-your-patients-can-use-aad-offers-sun-protection-counsel-in-advance-of-independence-day-holiday-weekend/2461819/Remind your patients to use sunscreen on the July 4th weekend and on the days, weeks, and months that follow. A recent American Academy of Dermatology (AAD) survey of more than 1,000 U.S. adults revealed that one-third of American parents reported having a child who
- Biosimilar News: Optum Rx Lists Cyltezo on Formularyhttps://practicaldermatology.com/news/biosimilar-news-optum-rx-lists-cyltezo-on-formulary/2461805/Optum Rx, a pharmacy benefit manager and subsidiary of UnitedHealth Group, will place Cyltezo (adalimumab-adbm) on its commercial formulary as a preferred brand, Boehringer Ingelheim reports. Cyltezo is a US Food and Drug Administration (FDA)-approved Interchangeable biosimilar to